TW202302113A - 用於治療肉瘤之化合物 - Google Patents

用於治療肉瘤之化合物 Download PDF

Info

Publication number
TW202302113A
TW202302113A TW111107759A TW111107759A TW202302113A TW 202302113 A TW202302113 A TW 202302113A TW 111107759 A TW111107759 A TW 111107759A TW 111107759 A TW111107759 A TW 111107759A TW 202302113 A TW202302113 A TW 202302113A
Authority
TW
Taiwan
Prior art keywords
dihydro
trifluoromethyl
phenyl
methyl
alkyl
Prior art date
Application number
TW111107759A
Other languages
English (en)
Chinese (zh)
Inventor
馬丁 藍居
史塔芬 卡福斯
夏洛特 克里絲汀 寇皮特斯
海蒂 格羅伊奇
曉筠 吳
馬修 邁伊爾森
Original Assignee
德商拜耳廠股份有限公司
美商博德研究所有限公司
美商達納 法伯癌症協會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商拜耳廠股份有限公司, 美商博德研究所有限公司, 美商達納 法伯癌症協會 filed Critical 德商拜耳廠股份有限公司
Publication of TW202302113A publication Critical patent/TW202302113A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111107759A 2021-03-03 2022-03-03 用於治療肉瘤之化合物 TW202302113A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163156193P 2021-03-03 2021-03-03
US63/156,193 2021-03-03

Publications (1)

Publication Number Publication Date
TW202302113A true TW202302113A (zh) 2023-01-16

Family

ID=80780814

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111107759A TW202302113A (zh) 2021-03-03 2022-03-03 用於治療肉瘤之化合物

Country Status (7)

Country Link
US (1) US20230405015A1 (enExample)
EP (1) EP4301371A1 (enExample)
JP (1) JP2024508171A (enExample)
CN (1) CN117279644A (enExample)
CA (1) CA3212314A1 (enExample)
TW (1) TW202302113A (enExample)
WO (1) WO2022184748A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120187704A (zh) * 2022-11-24 2025-06-20 盛睿泽华医药科技（苏州）有限公司 吡啶酮化合物及其制备方法和用途
CN118420559B (zh) * 2023-04-27 2025-02-14 上海超阳药业有限公司 氘代噁二嗪酮化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150361A (en) * 1998-12-22 2000-11-21 Bayer Corporation Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
JP6445573B2 (ja) * 2013-10-17 2018-12-26 サルタル セラピューティクス エルティーディＳａｒｔａｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物
CN106573931A (zh) * 2014-06-18 2017-04-19 拜耳医药股份有限公司 抑制BET蛋白的具有间位取代的芳族氨基或醚基的3，4‑二氢吡啶并[2，3‑b]吡嗪酮
WO2017027854A1 (en) * 2015-08-13 2017-02-16 The Broad Institute, Inc. Compositions and methods for cancer expressing pde3a or slfn12
TW201733591A (zh) * 2016-02-05 2017-10-01 拜耳製藥公司 用於癌症病人分級及癌症治療之化合物、組合物及方法
US11142522B2 (en) * 2017-02-03 2021-10-12 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment
JOP20200024A1 (ar) * 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون

Also Published As

Publication number Publication date
EP4301371A1 (en) 2024-01-10
JP2024508171A (ja) 2024-02-22
WO2022184748A1 (en) 2022-09-09
CN117279644A (zh) 2023-12-22
US20230405015A1 (en) 2023-12-21
CA3212314A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
US11964953B2 (en) Substituted aminothiazoles as DGKzeta inhibitors for immune activation
TWI887465B (zh) 用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法
EP3515916B1 (en) Shp2 phosphatase inhibitors and methods of use thereof
US20230064809A1 (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US11046699B2 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
WO2024079252A1 (en) Sos1 inhibitors
JP2025143330A (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
WO2019067843A1 (en) PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2
US20230357239A1 (en) Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
US10179123B2 (en) 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
MX2013005305A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
US20230017200A1 (en) Dihydrooxadiazinones
JP2018512403A (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
US20230405015A1 (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
JP2024521791A (ja) 脳又はｃｎｓへの癌転移を治療するためのｅｇｆｒデグレーダー
TW201625637A (zh) 經胺醇取代之２，３－二氫咪唑［１，２－ｃ］喹唑啉衍生物之給藥方案
US20210369724A1 (en) Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
EP4661870A1 (en) Combinations of dgk (diacylglycerol kinase) inhibitors
JP2017522332A (ja) アミノ置換イソオキサゾール類
HK40105245A (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
WO2018215282A1 (en) Combination of bub1 and pi3k inhibitors
US20200222414A1 (en) Combination of a pi3k-inhibitor with an androgen receptor antagonist
WO2018158175A1 (en) Combination of bub1 inhibitors
JP2018502863A (ja) 白血病の治療のための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用
WO2021260443A1 (en) Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines